Impact of KRAS G12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.
Enrique Caballé-PerezNorma Hernández-PedroMaritza Ramos-RamírezPedro Barrios-BernalEunice Romero-NuñezJosé Lucio-LozadaSantiago Avila-RíosGustavo Reyes-TeránAndrés Felipe CardonaOscar ArrietaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
To our knowledge, this study represents the first effort to comprehensively characterize the molecular heterogeneity of KRAS-mutant NSCLC in Latin American patients. Our data reinforce the current view that KRAS-mutated NSCLC is not a single oncogene-driven disease and emphasizes the prognostic impact of diverse molecular profiles in this genomically defined subset of NSCLC. Further validation is warranted in larger multicenter Latin American cohorts to confirm our findings.
Keyphrases
- advanced non small cell lung cancer
- wild type
- epidermal growth factor receptor
- small cell lung cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- prognostic factors
- single cell
- squamous cell carcinoma
- brain metastases
- single molecule
- tyrosine kinase
- patient reported outcomes
- big data
- skeletal muscle
- cross sectional
- clinical trial
- adipose tissue